CD19 and acute lymphoblastic leukemia: Immunoediting is also seen in highly selective clinical settings, specifically after the use of CD20-directed monoclonal antibodies and CD19-directed CAR-T cell therapy for ALL where CD20 and CD19 negative relapses are observed and facilitate escape from CAR-T cell killing45,46.